Sanofi (NYSE:SNY) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other equities research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Tuesday, April 25th. HSBC Holdings plc lowered shares of Sanofi from a “hold” rating to a “reduce” rating in a report on Friday, April 7th. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a report on Monday, April 24th. Argus boosted their price objective on shares of Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, June 9th. Finally, J P Morgan Chase & Co upgraded shares of Sanofi from an “underperform” rating to a “neutral” rating in a report on Tuesday, April 11th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $63.75.

Sanofi (NYSE:SNY) last announced its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.74. The firm had revenue of $8.66 billion during the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The firm’s revenue was down 2.3% on a year-over-year basis.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/07/sanofi-nysesny-rating-increased-to-hold-at-bidaskclub.html.

A number of large investors have recently bought and sold shares of the stock. Fisher Asset Management LLC raised its stake in Sanofi by 8.1% in the second quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock worth $653,419,000 after buying an additional 1,022,953 shares in the last quarter. Bank of America Corp DE raised its stake in Sanofi by 8.2% in the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock worth $340,792,000 after buying an additional 572,652 shares in the last quarter. Wells Fargo & Company MN raised its stake in Sanofi by 22.2% in the first quarter. Wells Fargo & Company MN now owns 4,492,719 shares of the company’s stock worth $203,296,000 after buying an additional 815,820 shares in the last quarter. Brandes Investment Partners LP raised its stake in Sanofi by 3.0% in the first quarter. Brandes Investment Partners LP now owns 3,490,226 shares of the company’s stock worth $157,933,000 after buying an additional 102,511 shares in the last quarter. Finally, Hamlin Capital Management LLC raised its stake in Sanofi by 11.8% in the first quarter. Hamlin Capital Management LLC now owns 1,768,523 shares of the company’s stock worth $80,026,000 after buying an additional 186,280 shares in the last quarter. Institutional investors own 9.97% of the company’s stock.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.